EDIT EDITAS MEDICINE INC revenue, earnings and financials

For the quarter ended June 30, 2026, EDITAS MEDICINE INC reported revenue of $11.9M (up 232.3% from a year earlier), net income of −$18.2M and diluted EPS of −$0.15; over the last four quarters revenue was $47.0M and net income −$73.9M; for the fiscal year ended December 2025 revenue was $40.5M, up 25.4% on the year before.

EDIT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $40.5M, gross profit n/a, operating income −$160M, net income −$160M (margin -395.0%), EPS −$1.80
• Fiscal year ended Dec 2024: revenue $32.3M, gross profit n/a, operating income −$251M, net income −$237M (margin -733.7%), EPS −$2.88
• Fiscal year ended Dec 2023: revenue $78.1M, gross profit n/a, operating income −$169M, net income −$153M (margin -196.1%), EPS −$2.02
• Fiscal year ended Dec 2022: revenue $19.7M, gross profit n/a, operating income −$226M, net income −$220M (margin -1118.3%), EPS −$3.21
• Fiscal year ended Dec 2021: revenue $25.5M, gross profit n/a, operating income −$193M, net income −$193M (margin -753.6%), EPS −$2.85

EDIT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $11.9M (up 232.3% year over year), net income −$18.2M, EPS −$0.15
• Quarter ended Mar 31, 2026: revenue $2.83M (down 39.2% year over year), net income −$25.0M, EPS −$0.26
• Quarter ended Dec 31, 2025 (from the annual report): revenue $24.7M (down 19.2% year over year), net income −$5.62M, EPS $0.03
• Quarter ended Sep 30, 2025: revenue $7.54M (up 12265.6% year over year), net income −$25.1M, EPS −$0.28
• Quarter ended Jun 30, 2025: revenue $3.58M (up 597.5% year over year), net income −$53.2M, EPS −$0.63
• Quarter ended Mar 31, 2025: revenue $4.66M (up 310.4% year over year), net income −$76.1M, EPS −$0.92
• Quarter ended Dec 31, 2024 (from the annual report): revenue $30.6M (down 49.0% year over year), net income −$45.4M, EPS −$0.55
• Quarter ended Sep 30, 2024: revenue $61.0K (down 98.9% year over year), net income −$62.1M, EPS −$0.75
• Quarter ended Jun 30, 2024: revenue $513K (down 82.2% year over year), net income −$67.6M, EPS −$0.82
• Quarter ended Mar 31, 2024: revenue $1.14M (down 88.5% year over year), net income −$62.0M, EPS −$0.76
• Quarter ended Dec 31, 2023 (from the annual report): revenue $60.0M (up 818.6% year over year), net income −$18.9M, EPS −$0.20
• Quarter ended Sep 30, 2023: revenue $5.34M (up 12604.8% year over year), net income −$45.0M, EPS −$0.55
• Quarter ended Jun 30, 2023: revenue $2.89M (down 54.6% year over year), net income −$40.3M, EPS −$0.56
• Quarter ended Mar 31, 2023: revenue $9.85M (up 45.5% year over year), net income −$49.0M, EPS −$0.71
• Quarter ended Dec 31, 2022 (from the annual report): revenue $6.54M (down 47.6% year over year), net income −$60.7M, EPS −$0.88
• Quarter ended Sep 30, 2022: revenue $42.0K (down 99.3% year over year), net income −$55.7M, EPS −$0.81
• Quarter ended Jun 30, 2022: revenue $6.36M (up 1578.6% year over year), net income −$53.5M, EPS −$0.78
• Quarter ended Mar 31, 2022: revenue $6.77M (up 4.2% year over year), net income −$50.5M, EPS −$0.74
• Quarter ended Dec 31, 2021 (from the annual report): revenue $12.5M, net income −$41.4M, EPS −$0.61
• Quarter ended Sep 30, 2021: revenue $6.20M, net income −$39.1M, EPS −$0.57

EDIT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$165M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$210M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$132M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$177M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$164M, share buybacks n/a

EDIT balance sheet

• Jun 30, 2026: cash $182M, total assets $237M, total liabilities $132M, shareholders' equity $105M, long-term debt $48.2M
• Mar 31, 2026: cash $124M, total assets $149M, total liabilities $145M, shareholders' equity $4.41M, long-term debt $47.2M
• Dec 31, 2025: cash $147M, total assets $187M, total liabilities $159M, shareholders' equity $27.3M, long-term debt $53.6M
• Sep 30, 2025: cash $166M, total assets $202M, total liabilities $188M, shareholders' equity $13.5M, long-term debt $54.1M
• Jun 30, 2025: cash $139M, total assets $211M, total liabilities $191M, shareholders' equity $19.2M, long-term debt $51.7M
• Mar 31, 2025: cash $139M, total assets $264M, total liabilities $201M, shareholders' equity $62.4M, long-term debt $49.6M
• Dec 31, 2024: cash $132M, total assets $342M, total liabilities $207M, shareholders' equity $134M, long-term debt $52.4M
• Sep 30, 2024: cash $95.8M, total assets $328M, total liabilities $152M, shareholders' equity $176M

What is EDIT's revenue?

EDITAS MEDICINE INC reported $47.0M of revenue over its last four quarters, through June 30, 2026.

Is EDIT profitable?

No. EDITAS MEDICINE INC lost $73.9M over the last four quarters.

What is EDIT's EPS?

Diluted earnings per share over the last four quarters were −$0.66; −$0.15 in the latest quarter.

EDIT ownership and insider trades · All stocks